Audit: QRS - BITC for Health & Longevity

Audit conducted on 07/09/2026 02:23 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated variable: 200 mg nasturtium / 80 mg horseradish (ER 333), 57 mg glucotropaeolin per gram (ER 335), 76.7% vs 16.7% (ER 179), ~90 days / day 3 / 84 days (ER 165, 324, 386), all seven biomarker rows (ER 418–424).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“from observation alone” and “Purified compound: never given to a person” preserve the ER’s hedging (ER 455); “No established target” carried verbatim into marker_2_target.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications carried at full strength; “Pregnancy and lactation” remains an absolute stop item, not a caution.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications come from the ER’s “Populations who should avoid BITC” list; interactions from the ER interaction bullets; no Benefit- or Risk-Modifying Factor was migrated into a gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no NCT identifiers, no author names and no brand name (Angocin / Repha are not surfaced).
1.6	The QRS does not introduce new attributions.	🟢	No attribution of any kind appears outside the fixed template header.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s restrained, evidence-limited register (“tested largely by its maker”, “from observation alone”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified where the ER quantifies, plain-language where it can be; presents the food-level route as a usable option rather than dismissing the compound.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is declarative and descriptive throughout; no instruction is issued to a reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Cadence and gate items are stated as observations of what the trials and the licensed product’s labelling do, not as directions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “recommend”, “advise”, “should” or equivalent in the QRS’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the file; no imperative constructions.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	“dysuria” is glossed as “(pain on urination)”; the remaining technical terms (CYP2E1, eGFR, TSH) are unavoidable biomarker and drug-class names carried from the ER.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, benefit and risk is a stripped noun phrase; monitoring “Why” cells are single clauses.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for “you” / “your” / “we”: no matches.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	The sheet assumes willingness to run baseline urinalysis, urinary iodine and thyroid panels before use.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Retains the 4-tablets-three-times-daily schedule and a seven-marker laboratory panel including a research-laboratory cyclocondensation assay.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward a mass-market “just eat more cress” framing; the evidence limits are stated bluntly.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance leads with the sponsorship limitation and the absence of any purified-compound human data — the two facts that matter most to a proactive self-experimenter.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” appears only in the title, carried from the ER canonical_topic; “anti-aging” does not appear.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“film-coated tablet”, “mucosal irritation”, “hypersensitivity reactions”, “urothelial carcinoma” — no consumer-grade substitutions.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified verbatim at lines 446, 492, 542, 570, 591, 617, 642, 646–648, 744; tier labels intact at 545/549/555/559 and 620/623/627/632.
3.2	All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variable names present; the repeatable marker_#* and qualitative_item# spans are instantiated as marker_1–7 and qualitative_item_1–6 (61 spans total).
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Structural diff against the template shows changes confined to variable content, frontmatter values and instantiated repeatable rows; CSS, markup, website= spans and footer disclaimer are byte-identical.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the High benefit and High risk tiers carry explanatory prose in the ER and are governed by items 12.5 / 13.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Licensed fixed-combination approach”, “Whole-food approach” and “Single versus split dosing” are the ER’s bold labels verbatim (ER 333, 335, 345).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol labels verbatim; monitoring row labels match the ER biomarker table names; time-to-effect labels name the ER’s own outcome headings, which the ER supplies no bold label for.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Full-text scan for emoji code points returns no matches; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed against the ER: 11 interaction bullets reduced to single noun phrases with trimmed drug lists, 7 contraindications stripped of trailing rationale, biomarker “Why” cells cut to one clause each, cadence reduced to two sentences.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Comment opens at line 2 immediately after the doctype at line 1 and closes at line 14, ahead of every other comment and all head content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the preceding “QRS — Metadata (invisible, parsed by audit tooling)” text sits before the opener as permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed entirely in an HTML comment; none of its values are repeated in the body except header_subline_date/model, which are their own template variables.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, and it contains a colon requiring YAML quoting; all other values unquoted and untrimmed of nothing.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: bitc_2026-0907-0010_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0907-0155, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version, no qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version only, no context-window or tier qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: bitc_2026-0907-0010_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; the added git_user and git_issue values are bare and unquoted as required.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “BITC for Health & Longevity - Quick Reference Sheet”; matches ER canonical_topic with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “BITC for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/07/2026”, correctly derived from qrs_creation_date 2026-0907-0155.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line was correctly not carried across.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Tracks the Conclusion’s structure exactly: single reactive property → dual effect → what the human evidence actually is → what has never been tested (ER 453–457).
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“reactive plant defense chemical” (ER 453); “cress and nasturtium” (ER 37); “appetite for sulfur groups” / “irritates the surfaces it touches” (ER 453); “tested largely by its maker” (ER 455); “slower spread” from observation (ER 455); “never given to a person” (ER 455).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “isothiocyanate”, “glucotropaeolin”, “urothelial” and “non–muscle-invasive” are all kept out of this section in favour of “sulfur groups”, “bladder”, “airway”.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, author, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No hazard ratios, percentages or confidence intervals; “fewer” and “slower” carry the direction without numbers.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to the “Populations who should avoid BITC” list at ER 303–311.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete 7-of-7 coverage with no additions.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the stop_items span, lines 573–586.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale correctly stripped: “in whom the licensed preparation is not authorized”, “where no safety data exist for any isothiocyanate preparation” and “given the unresolved rodent bladder findings” all removed; no dashes remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(urinary iodine below 100 µg/L)” preserved; the eGFR threshold “below 30 mL/min/1.73 m²”, the age cut-off “under 6 years” and the staging qualifier “under surveillance without urologist involvement” are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s contraindication list uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven such populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –>	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eleven items map one-to-one onto the ER interaction bullets at ER 281–301.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Complete 11-of-11 coverage; none duplicates a stop item — “Iodine, kelp and thyroid hormone replacement” is the interaction bullet, distinct from the iodine-deficiency contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eleven <li> elements inside the caution_items span, lines 594–607.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Caution.”/”Monitor.” verdict and its mechanistic sentence stripped; the Conrad et al. citation on the antibiotics bullet (ER 301) correctly dropped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All seven ER parenthetical drug lists retained and trimmed, never dropped: CYP2E1, CYP2A6, antiplatelet, OTC irritant, antacid, isothiocyanate-supplement and urinary-antibacterial lists each keep representative examples.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking notation.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eleven interactions, and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –>	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three action sets trace to the ER “Therapeutic Protocol” section (ER 331–355).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Licensed dose, whole-food alternative and split-dosing schedule are the three bullets that can actually be acted on; the remaining bullets are framing, pharmacokinetics or modifier discussion.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies well over three actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine variables populated; values “4 tablets, 3× daily”, “Cress, nasturtium or papaya seed” and “Split, without exception in the human record” all trace to ER 333, 335 and 345.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Recurrent UTI, respiratory tract infection and parasite clearance are the only three outcomes in the ER with a stated time course (ER 165, 179, 324, 386).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered UTI → RTI → parasites, matching the ER’s Medium → Medium → Low benefit tiering; bladder-cancer progression is correctly omitted since the ER gives it no time course.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine variables populated; time_1_sub is verbatim from ER 386 and time_3_sub from ER 179.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Tier membership matches the ER’s Medium / Low / Speculative headings exactly (ER 155–197).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 544, 547, 554, 557.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	All Magnitude figures, sponsorship caveats and mechanistic paragraphs dropped; each item is a bare outcome phrase.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any benefit item; the “(disease confined to the lining)” gloss from ER 169 correctly dropped.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High-tier benefit (ER 151); benefits_high carries style="display: none" at line 544 with no empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Tier membership matches the ER’s Medium / Low / Speculative headings exactly (ER 227–263).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 619, 622, 625, 630.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	The 1.5%-vs-6.8% adverse-event figures (ER 231) and all mechanistic prose stripped; each item is a bare risk phrase.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses in any risk item; the “(thyroid enlargement)” gloss from ER 243 correctly dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER has no High-tier risk (ER 223); risks_high carries style="display: none" at line 619 with no empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows trace to the biomarker table in “Monitoring Protocol & Defining Success” (ER 416–424).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	7 of 7 carried in ER order: urinalysis with microscopy, urinary total isothiocyanates, TSH, free T4, urinary iodine, creatinine/eGFR, ALT/AST.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 736: “Baseline, 4 weeks, 12 weeks, then every 6 to 12 months on repeated prophylaxis courses. Acute short courses need no interval testing.” — condensed from ER 414.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items trace to the qualitative-marker list at ER 428–433.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	6 of 6 carried in ER order: gastric comfort, mucosal burning, urinary symptoms, respiratory-infection frequency, rash/itch/wheeze, energy and cold intolerance.

Issues 07/09/2026 02:23

Pass rate 100.00%. No issues found.

Issues 07/09/2026 02:15

1. 1.1 / 7.3 — At-a-glance misattributes human evidence: [at_a_glance] (lines 434–438) states that all the human evidence, including “slower spread of treated bladder cancer”, “comes from one licensed herbal product tested largely by its maker”; the ER Conclusion (line 455) sources that finding to blood and urine measurements in people “who were observed rather than assigned”, not to the licensed preparation.
2. 1.3 — Split-dosing claim strengthened: [action_3_value] (line 481) reads “Split, without exception”, dropping the ER’s qualifier “in the human record” (ER line 345) and turning a statement about the evidence base into an absolute rule.

Fixes 07/09/2026 02:15

1. 1.1 / 7.3 — At-a-glance evidence attribution corrected: Rewrote [at_a_glance] so the licensed herbal product is credited only with the infection findings, and the bladder-cancer progression signal is attributed to observation, changing “Human evidence — fewer repeat bladder and airway infections, slower spread of treated bladder cancer — comes from one licensed herbal product tested largely by its maker” to “Fewer repeat bladder and airway infections come from one licensed herbal product tested largely by its maker; slower spread of treated bladder cancer, from observation alone.”
2. 1.3 — Split-dosing qualifier restored: Changed [action_3_value] from “Split, without exception” to “Split, without exception in the human record”, matching the ER wording.

Issues 07/09/2026 02:09

1. 4.5 — Exceeds the one A4 page budget: Uncondensed ER prose is carried into the three densest blocks — the seven Monitoring Why cells keep full ER sentences (e.g. marker_6_why, line 735), all six qualitative_item_# entries keep their ER trailing clauses (lines 773-807), and all eleven caution_items carry four-drug parenthetical lists (lines 593-611) — pushing the estimated rendered height to roughly 1.4-1.8 A4 pages.

Fixes 07/09/2026 02:09

1. 4.5 — Monitoring table condensed: Shortened the Why cells for markers 2, 5, 6 and 7 and the Target cell for marker 7 (e.g. marker_6_why from “The licensed preparation is contraindicated in acute kidney inflammation and below 30 mL/min/1.73 m²” to “Contraindicated below 30 mL/min/1.73 m²”), removing roughly one wrapped line per row across all seven rows.
2. 4.5 — Qualitative items trimmed: Stripped the ER explanatory trailing clauses from qualitative_item_2, _3, _5 and _6 (e.g. “Skin rash, itching or wheeze, as the earliest signal of sensitization” to “Skin rash, itching or wheeze”), keeping all six items but reducing each to a single line.
3. 4.5 — Key Interactions parentheticals trimmed: Reduced the example-drug lists in the caution_items gate from four drugs to two or three per item (e.g. “CYP2E1 substrates (acetaminophen, chlorzoxazone, isoflurane, ethanol)” to “CYP2E1 substrates (acetaminophen, ethanol)”), retaining all eleven items and every parenthetical.
4. 4.5 — Protocol and cadence tightened: Shortened action_2_sub, action_3_sub and monitoring_cadence (cadence from “Baseline, then repeat at 4 weeks, again at 12 weeks, and thereafter every 6 to 12 months for anyone on repeated prophylaxis courses” to “Baseline, 4 weeks, 12 weeks, then every 6 to 12 months on repeated prophylaxis courses”).

Issues 07/09/2026 02:01

1. 11.2 — Time-to-effect order ignores benefit tier: The Time to Effect cells are ordered by ascending duration rather than by benefit magnitude — Clearance of Intestinal Parasites (a Low-tier benefit) sits at time_1 (line 498) ahead of Respiratory Tract Infection and Recurrent Urinary Tract Infection, both Medium-tier.

Fixes 07/09/2026 02:01

1. 11.2 — Time-to-effect reordered by benefit tier: Reordered the three Time to Effect cells from ascending-duration order to benefit magnitude — time_1 is now Recurrent Urinary Tract Infection (Medium), time_2 Respiratory Tract Infection (Medium), and time_3 Clearance of Intestinal Parasites (Low), matching the ER’s benefit tiering and within-tier order.